AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00810134 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Thrupass
Description: Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
Study NCT00810134 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bypass
Description: Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft
Study NCT00319098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted pandemic influenza candidate vaccine
Description: 2 doses, intramuscular injection
Study NCT00319098 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix
Description: One intramuscular injection
Study NCT00319098 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One intramuscular injection
Study NCT03093194 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vaginal preparation before CS with Septal soap and septol.
Description: vaginal preparation before CS with Septal soap and septol.
Study NCT03093194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No vaginal preparation before CS with Septal soap and septol.
Description: No vaginal preparation before CS with Septal soap and septol.
Study NCT03077477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMXT 1501
Description: Study treatment will be provided in tablet form; each containing 128 mg AMXT 1501 dicaprate salt, 80 mg of which is AMXT 1501 freebase (active drug), plus excipients and are orally administered.
Study NCT03077477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMXT 1501
Description: Study treatment will be provided in tablet form; each containing 128 mg AMXT 1501 dicaprate salt, 80 mg of which is AMXT 1501 freebase (active drug), plus excipients and are orally administered.
Study NCT03077477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Reference Therapy, Dose and Route of Administration:~Placebo Tablets, orally administered
Study NCT04295408 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pericapsular nerve group block with saline solution
Description: A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 100-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the saline solution was injected in 5-mL increments while observing for adequate fluid spread in this plane.a total volune of 40 ml saline solution was injected.
Study NCT04295408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block with ropivacaine
Description: A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 100-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, local anesthetic was injected in 5-mL increments while observing for adequate fluid spread in this plane. a 2 mg.kg-1Ropivacaine in 40 ml of saline was injected
Study NCT01173523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090
Study NCT03346629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone + Misoprostol
Description: A single dose of 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed 24-48 hours later with 400mcg misoprostol (buccal) at home. The participant will return to the hospital one to two hours after taking the initial dose of misoprostol to receive repeated doses of 400 mcg misoprostol until the abortion occurs.
Study NCT00951600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxcarbazepine 300 mg/5mL oral suspension
Study NCT00951600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxcarbazepine 300 mg/5mL oral suspension
Study NCT02564575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPIV3-EbovZ GP Vaccine
Description: Administered intranasally by a VaxINator device
Study NCT00081367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Participants will receive ten weekly sessions of treatment. Suicidal thoughts or attempts, hopelessness, depression, health care utilization, and overall psychological and social adaptation will be assessed.
Study NCT00081367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care alone
Description: Participants will receive standard care for suicide prevention.
Study NCT00771901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tauroursodeoxycholic acid
Description: 1750 mg/day for four weeks. Seven pills daily, 2 with breakfast, 2 with lunch, and 3 with dinner.
Study NCT00771901 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 7 pills daily for 4 weeks
Study NCT00771901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phenylbutyrate
Description: 20g/day for four weeks.
Study NCT01672814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: riboflavin ophthalmic solution
Description: Administration of riboflavin every 2 minutes for 20 minutes
Study NCT01672814 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vedera KXS Microwave System
Description: The Vedera KXS dose will be based on the pre-treatment manifest refraction spherical equivalent (MRSE), to be administered one day prior to the CXL procedure.
Study NCT01060631 — intervention group
Intervention type: DEVICE
Intervention: BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations
Description: Difference between left- and rightsided BIS values in patients with supratentorial brain tumor during course and Comparison between predicted and measured propofol plasma concentrations during course of the study
Study NCT00081367 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care alone
Description: Participants will receive standard care for suicide prevention.
Study NCT02266966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F2695
Study NCT02266966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00762125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CR+ST
Description: Addresses maladaptive beliefs in general and includes education and training in the use of specific coping strategies
Study NCT00762125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ET
Description: Addresses beliefs and emotional arousal during confrontations with feared element (exercising) through use of counter-conditioning and corrective feedback
Study NCT00762125 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AC treatment
Description: Provides support and controls for nonspecific factors associated with exposure to therapists and other FMS sufferers, but does not directly address either maladaptive beliefs or emotional arousal
Study NCT02715128 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: non-invasive electric brain stimulation method
Study NCT02715128 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: non-invasive electric brain stimulation method
Study NCT03825380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Description: Eyedrops
Study NCT03825380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumigan®
Description: Eyedrops
Study NCT03738540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TALK study group
Description: Telephone Delivered Intervention
Study NCT03738540 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TALK control group
Description: Telephone Delivered Intervention
Study NCT01063257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: The dosage of Clofarabine will be gradually augmented in a 3+3 design for each following dose level:~DL1 - 5mg/m2/d, DL2 - 7.5mg/m2/d, DL3 - 10mg/m2/d, DL4 - 12.5mg/m2/d (This dose may not be reached and is an optional dose level in case the MTD is not reached before and depending on further data from the ongoing MDS Phase IIa oral formulation trial).~The DLa will be the following:~DL1a - 2.5mg/m2/d, DL2a - 6.5mg/m2/d, DL3a - 8.5mg/m2/d, DL4a - 11.5mg/m2/d (In case of activation of the DL4 step). Dose levels 1a, 2a and 3a will be used for de-escalation.
Study NCT01926106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nIPPV
Description: one of the twins was randomly allocated to nIPPV
Study NCT01926106 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP
Description: another of the twins was allocated to nCPAP
Study NCT00395876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 mL of placebo instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of placebo). Patients weighing \< 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
Study NCT00395876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 2 mL of placebo instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of placebo). Patients weighing \< 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
Study NCT00395876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tenecteplase
Description: 2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of tenecteplase). Patients weighing \< 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
Study NCT00395876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenecteplase
Description: 2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of tenecteplase). Patients weighing \< 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
Study NCT04523545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cardiac ablation
Description: cardiac ablation using pulsed electric field energy to cause pulmonary vein isolation
Study NCT00906672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTEGRA®
Description: A plaque of dermal substitute Integra® is adjusted to the size of the wound and sutured. A negative pressure bandage is placed on the wound. 7 to 11 days post surgery, the Integra® silicone layer is removed and the neoderm is covered with a skin graft.
Study NCT00101205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00101205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT02162030 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Commitment Therapy
Description: Half of the participants will receive an eight-session ACT intervention whereby each component of the psychological flexibility model will be covered. Half of the participants will receive an eight-session act intervention whereby each component except self as context will be covered.
Study NCT03779516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Effect of saline on postoperative sore throat
Study NCT03779516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Effect of nebulized lidocaine on postoperative sore throat
Study NCT00612482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: drug prevention curriculum
Description: Participants in the experimental arm of the study will receive the 5-lesson, science-based drug prevention curriculum in their science classes.
Study NCT05234242 — intervention group
Intervention type: PROCEDURE
Intervention: inguinal hernia repair
Description: inguinal hernia repair performed either in stationary/inpatient or ambulatory/outpatient setting
Study NCT04540120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapansutrile capsules
Description: Hard opaque capsules containing 250 mg of API.
Study NCT04540120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules
Description: Hard opaque capsules containing 0 mg of API.
Study NCT03289637 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D intervention tested against placebo in a population with heart failure and a 25-OH-vitamin D level\<50nmol/L at screening
Study NCT03289637 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D intervention tested against placebo in a population with heart failure and a 25-OH-vitamin D level\<50nmol/L at screening
Study NCT03744988 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum androgen levels
Description: measurement of serum free and total testosterone
Study NCT01864473 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Kshar Sutra
Description: The Kshar Sutra is a standard medicated thread smeared with Kshar of Apamarga (Achyranthus Aspera), Shnuhi (Euforbia Nerrifolia) which has quality of cutting and Haridra (Curcuma longa) which is used as a antiseptic. This combination of medicine on the thread helps in debridement and simultaneously healing of track. After conformation of vaginal fistula the track was cleaned with betadine and Hydrogen peroxide. The Kshar Sutra was tied covering the entire underlying track for simultaneous cutting and healing under all aseptic precaution. The patient was discharged on the next day of procedure. Patient was advice for Sitz bath with lukewarm water. The Kshar Sutra was changed weekly.
Study NCT02571725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib starts concomitantly with the first dose of Tremelimumab
Study NCT02571725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 3 to 6 patients will be treated at 10 mg/kg depending on RLT observed in the first 3 patients. If 0 out of 3 or 1 out of 6 patients experienced a RLT at 10 mg/kg, then this dose will be considered at the recommended phase 2 dose (RP2D). If 2 out of 6 patients experience RLT at this dose within 56 days, then dose reductions as detailed in the Arm description will be carried out.
Study NCT03053622 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mirikizumab Test
Description: Administered SC
Study NCT03053622 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mirikizumab Test
Description: Administered IV
Study NCT03053622 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mirikizumab Reference
Description: Administered SC
Study NCT03254719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Study assessments
Description: All participants will be asked to complete study assessments at baseline visit, and weeks 3, 5, 7, and 10. Study participants will receive spinal manipulation and appropriate adjunctive therapies provided by doctors of chiropractic.
Study NCT02577042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.
Study NCT02577042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PI-based regimen
Description: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.
Study NCT02577042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks
Study NCT02577042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks
Study NCT01796860 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: AFO
Description: The purpose of this study is to investigate the impact of a specifically designed ankle foot orthosis (AFO, hinged, with tamarack joint and adjustable check strap) on the spatial and temporal gait parameters, electromyography (EMG), and walking endurance, in select individuals living with MS. Over the 13 week period, the subject will participate in 5 gait training sessions which will be at weeks 1, 2, 3, 7, and 10.
Study NCT01884870 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical Treatment
Description: Surgical Treatment - open, endoscopic or laparoscopic
Study NCT00896883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Middle Turbinate Implant
Description: Middle Turbinate Implant placement at time of surgery and follow ups.
Study NCT00305110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg IV hydromorphone
Study NCT02713503 — intervention group
Intervention type: OTHER
Intervention: Driving Observation
Description: Driving observation using the DriveSafety CDS-250 Driving Simulator.
Study NCT02713503 — intervention group
Intervention type: OTHER
Intervention: VisionCoach
Description: Visual field evaluation using VisionCoach
Study NCT01279590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPD10558
Description: PPD10558 40 mg capsule and matching placebo capsule twice a day for 4 weeks, then~PPD10558 80 mg (two 40 mg capsules) twice a day for 8 weeks
Study NCT01279590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 40 mg capsule and matching placebo capsule in the morning and 2 placebo capsules in the evening for 4 weeks, then~Atorvastatin 80 mg (two 40 mg capsules) in the morning and 2 placebo capsules in the evening for 8 weeks
Study NCT01279590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo capsules twice daily for 12 weeks
Study NCT03826485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRIC
Description: Pranlukast hydrate 50mg
Study NCT03826485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pranlukast hydrate
Description: Pranlukast hydrate 225mg/2.25g
Study NCT01595490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Skills Group
Description: Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
Study NCT00459589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional intervention with dietician plus usual nutritional care
Description: nutritional intervention with dietician at each cycle of chemotherapy in 6 first cycles to maintain 30 kcal/kg/d and 1.2 protein/kg/d
Study NCT00459589 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual nutritional care
Description: usual nutritional care
Study NCT00950599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 2.5 mg, once daily, 12 weeks
Study NCT00950599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 5 mg, once daily, 12 weeks
Study NCT00950599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 10 mg, once daily, 12 weeks
Study NCT00950599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 20 mg, once daily, 12 weeks
Study NCT00950599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 40 mg, once daily, 12 weeks
Study NCT00950599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 100 mg, once daily, 6 weeks
Study NCT00950599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, once daily, 6 and 12 weeks
Study NCT00459381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given orally
Study NCT00459381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00764049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single pass albumin dialysis
Description: 6 hours sessions of albumin dialysis.
Study NCT03104088 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CANTAB
Description: CANTAB Cognitive Assessment (tablet based cognitive testing from CAMCOG)
Study NCT03104088 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MOCA
Description: Montreal cognitive assessment (MOCA) in German